InvestSMART

EMvision Medical Devices Limited (ASX:EMV)

ALERT: Price-sensitive ASX Announcement for EMV
Current share price for EMV : $1.500 -0.055 (-3.54%)+
Announcement
Release
13 Apr 2026 9:04AM
Price at Release
$1.555
Full Release
download
Summary
EMVision Medical Devices Limited, an Australian company, has released its Quarterly Activities and Appendix 4C Cash Flow Report for the period ending 31 March 2026. The report highlights the company's progress in the Pivotal (Validation) Trial for its emu™ Brain Scanner, recruitment efforts at eight leading hospitals, and growing international clinical awareness of its technology. The company has reported cash reserves of $18.4 million as of the quarter's end, supported by grant programs providing additional non-dilutive funding. Significant grants include those from the Australian Stroke Alliance and the CRC-P Program. During the quarter, EMVision received an R&D tax refund of $3.8 million and continued advancing its First Responder pre-hospital program with multiple feasibility studies. The report also outlines cash inflows and expenditures, including R&D and staff costs, emphasizing the company's financial and operational strategies to support its commercialisation milestones.
Key Points
  • EMVision is advancing its Pivotal (Validation) Trial for FDA De Novo clearance.
  • Eight hospitals are actively recruiting for the trial with no device-related adverse events reported.
  • EMVision's technology featured at the NABI Conference in Texas and in a forthcoming US academic paper.
  • Pre-hospital feasibility studies for the First Responder device are nearing completion.
  • Cash reserves of $18.4 million as of 31 March 2026, with additional grant funding available.
  • Received $3.8 million R&D tax refund for FY25.
  • Significant grant support from Australian Stroke Alliance and CRC-P Program.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.